Vertex Pharmaceuticals Incorporated VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. The company primarily focuses on developing transformative therapies for cystic fibrosis (CF), sickle cell disease, beta thalassemia, and acute pain, with a strong pipeline in other areas such as type 1 diabetes, APOL1-mediated kidney diseases, and muscular dystrophies. Vertex serves patients worldwide through its commercial operations in North America, Europe, and other international markets, generating revenue primarily from the sale of its proprietary pharmaceutical products. The company operates through a research-driven business model that combines deep scientific expertise with targeted commercialization efforts. Vertex invests heavily in research and development to advance its pipeline of small molecule drugs, cell and genetic therapies, and other novel treatment modalities. Its most significant commercial success comes from its portfolio of CF therapies, including TRIKAFTA/KAFTRIO, which represents the majority of its product revenues. The company also engages in strategic collaborations and acquisitions, such as its partnership with CRISPR Therapeutics for CASGEVY and its acquisition of Alpine Immune Sciences, to expand its therapeutic capabilities and pipeline.
LSTM Forecast
Forecast model is not trained yet for this market.
Train and backfill the LSTM forecast to surface a directional view here.